


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (Cancelled).

6. (Currently amended): A compound of formula (i) or a pharmaceutically acceptable salt thereof:



wherein

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

R³ represents hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;


R^{3a} and R⁵ independently represent hydrogen or C₁₋₆ alkyl;

R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n represents 1 or 2; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;
~~or solvates thereof.~~

7. (Currently amended): A compound of formula (ii) or a pharmaceutically acceptable salt thereof:



(ii)

wherein

R^1 and R^2 independently represent hydrogen or C_{1-6} alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

R^3 represents hydrogen, halogen, cyano, $-CF_3$, $-OCF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl or a group $-CONR^6R^7$;


R^{3a} and R^5 independently represent hydrogen or C_{1-6} alkyl;

R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n represents 1 or 2; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;
~~or solvates thereof.~~

8. (Currently amended): A compound of formula (iii) or a pharmaceutically acceptable salt thereof:



(iii)

wherein

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

R³ and R⁴ independently represent hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;


n represents 1 or 2;

s represents an integer from 1 to 3; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;

~~or solvates thereof.~~

9. (Currently amended): A compound of formula (iv) or a pharmaceutically acceptable salt thereof:



(iv)

wherein

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

R³ and R⁴ independently represent hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

q represents 1 or 2;

r represents an integer from 1 to 3; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;

~~or solvates thereof.~~

10. (Previously presented): A compound according to claim 6 which is:
4-(3-Phenylsulfonyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)-piperazine hydrochloride;
4-Methyl-7-piperazin-1-yl-3-phenylsulfonyl-4*H*-pyrrolo[3,2-*b*] pyridine;
1-Methyl-7-piperazin-1-yl-3-phenylsulfonyl-1*H*-pyrrolo[3,2-*b*] pyridine;
1-Methyl-7-piperazin-1-yl-3-(2-fluorophenyl)sulfonyl-1*H*-pyrrolo[3,2-*b*] pyridine;
4-Methyl-7-piperazin-1-yl-3-(2-fluorophenyl)sulfonyl-4*H*-pyrrolo[3,2-*b*] pyridine;
or a pharmaceutically acceptable salt thereof.

11. (Previously presented): A compound according to claim 7 which is:
7-Piperazin-1-yl-3-phenylsulfonyl-1*H*-pyrrolo[2,3-*c*] pyridine hydrochloride;
3-(2-Fluorophenyl)sulfonyl-7-piperazin-1-yl-1*H*-pyrrolo[2,3-*c*]pyridine hydrochloride;
3-(3-Fluorophenyl)sulfonyl-7-piperazin-1-yl-1*H*-pyrrolo[2,3-*c*]pyridine hydrochloride;
or a pharmaceutically acceptable salt thereof.

12. (Previously presented): A compound according to claim 8 which is:
2-Methyl-4-piperazin-1-yl-7-phenylsulfonylquinoline hydrochloride;
or a pharmaceutically acceptable salt thereof.

13. (Previously presented): A compound according to claim 9 which is:
4-Phenylsulfonyl-8-piperazin-1-yl quinoline;
4-Phenylsulfonyl-8-piperazin-1-yl-quinoline hydrochloride;
2-Methyl -4-phenylsulfonyl-8-piperazin-1-yl-quinoline;
2-Methyl-4-phenylsulfonyl-8-piperazin-1-ylquinoline hydrochloride;
2-Methyl-4-(2-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;
2-Methyl-4-(3-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;
2-Methyl-4-(3-chlorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;
or a pharmaceutically acceptable salt thereof.

14. (Currently amended): A pharmaceutical composition which comprises ~~[[a]]~~ the compound according to claim 6 and a pharmaceutically acceptable carrier or excipient.

15. (Currently amended): A pharmaceutical composition which comprises ~~[[a]]~~ the compound according to claim 7 and a pharmaceutically acceptable carrier or excipient.

16. (Currently amended): A pharmaceutical composition which comprises ~~[[a]]~~ the compound according to claim 8 and a pharmaceutically acceptable carrier or excipient.

17. (Currently amended): A pharmaceutical composition which comprises ~~[[a]]~~ the compound according to claim 9 and a pharmaceutically acceptable carrier or excipient.

18. (Currently amended): A method of treating disease selected from the group depression, anxiety, obesity and cognitive memory disorders which comprises administering a ~~safe and~~ therapeutically effective amount₂ to a patient in need thereof₂ of ~~[[a]]~~ the compound as defined in claim 6 or a pharmaceutically acceptable salt thereof.

19. (Currently amended): A method of treating disease selected from the group depression, anxiety, obesity and cognitive memory disorders which comprises administering a ~~safe and~~ therapeutically effective amount₂ to a patient in need thereof₂ of ~~[[a]]~~ the compound as defined in claim 7 or a pharmaceutically acceptable salt thereof.

20. (Currently amended): A method of treating disease selected from the group depression, anxiety, obesity and cognitive memory disorders which comprises administering a ~~safe and~~ therapeutically effective amount₂ to a patient in need thereof₂ of ~~[[a]]~~ the compound as defined in claim 8 or a pharmaceutically acceptable salt thereof.

21. (Currently amended): A method of treating a disease selected from the group depression, anxiety, obesity and cognitive memory disorders which comprises administering a ~~safe and~~ therapeutically effective amount₂ to a patient in need thereof₂ of ~~[[a]]~~ the compound as defined in claim 9 or a pharmaceutically acceptable salt thereof.